New drug combo shows promise in shrinking cervical tumors before surgery
NCT ID NCT07205497
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 35 times
Summary
This phase 2 trial tests whether adding the immunotherapy drug QL1706 to standard chemotherapy before hysterectomy can improve outcomes for people with locally advanced cervical cancer. About 54 participants will receive three cycles of the combination, then surgery if the tumor shrinks enough. Researchers will measure how many patients have no cancer left after treatment and track side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED CERVICAL CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
The Sun Yat-sen Memorial Hospital of the Sun Yat-sen University
Guangzhou, Guangdong, 537216, China
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Iparomlimab and tuvonralimab (QL1706) combined with cisplatin and albumin-bound paclitaxel
What this could lead to
If this works, it could offer a more effective treatment option for locally advanced cervical cancer, potentially improving survival and reducing the need for more extensive surgery.
What could go wrong
This is an early phase 2 trial with only 54 participants, so results may not apply to everyone. The drug combination may cause significant side effects, and it is not yet proven to be better than standard care.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.